CHOLANGIOCARCINOMA MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Cholangiocarcinoma Market, By Cancer Type [Extrahepatic Cholangiocarcinoma (Perihilar, Distal), Intrahepatic Cholangiocarcinoma], By Therapy Type [Targeted Drug Therapy (Pemigatinib, Ivosidenib, Futibatinib, Infigratinib), Chemotherapy (5-Fluorouracil, Gemcitabine, Cisplatin, Capecitabine, Oxaliplatin), Immunotherapy (Pembrolizumab, and Others), and Others (Pain Medications and Others)], By Route of Administration (Oral, Subcutaneous, and Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-commerce), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In: 25 Mar, 2025
Code: CMI4435
Pages: 156
Formats: Excel and PDF
Industry: Pharmaceutical
- Historical Range: 2020 - 2024
- Forecast Period: 2025 - 2032

Bile duct cancer is also called as cholangiocarcinoma. Cholangiocarcinoma is a form of cancer in which epithelial cells are mutated, which means the cells show characters of epithelial differentiation in the bile duct. The bile duct carries a fluid called bile, which is secreted in the liver and stored in the gall bladder. The essential function of bile is to breakdown the fats during digestion. Signs of bile duct cancer include jaundice and pain in the abdomen. There are two types of bile duct cancer intrahepatic bile duct cancer and extrahepatic bile duct cancer. Intrahepatic bile duct cancer occurs in the parts of the bile ducts within the liver. Extrahepatic bile duct cancer is a rare cancer that forms in the bile ducts outside the liver.

Market Dynamics

Key players operating in the global cholangiocarcinoma market are focusing on adoption of inorganic growth strategies such as collaborations, which are expected to drive the market growth during the forecast period. For instance, In March 2021, QED Therapeutics collaborated with Helsinn Group, is a privately-owned Swiss Pharma Company. The collaboration intends to co-develop and commercialize Infigratinib, an oral FGFR1-3 selective inhibitor, for patients dealing with cholangiocarcinoma (bile duct cancer). Moreover, In February 2019, Imbrium Therapeutics L.P., in collaboration with Mundipharma EDO GmbH, a part of the Mundipharma-network, announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to its investigational drug etoposide toniribate, a novel topoisomerase II inhibitor, for the treatment of relapsed refractory biliary tract cancer.

Key features of the study:

This report provides an in-depth analysis of the global cholangiocarcinoma market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cholangiocarcinoma market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global cholangiocarcinoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global cholangiocarcinoma market

Detailed Segmentation:

Global Cholangiocarcinoma Market, By Treatment Type:
- Chemotherapy
  - Gemcitabine
  - Cisplatin
  - Oxaliplatin
  - Capecitabine
  - 5 fluorouracil (5-FU)
- Targeted Therapy
  - Pemigatinib
  - Infigratinib (Phase 3)
  - Ivosidenib (Phase 3)
- Immunotherapy
  - Pembrolizumab (Phase 3)
- Others
Global Cholangiocarcinoma Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Cholangiocarcinoma Market, By Region:
- North America
  - By Treatment Type
    - Chemotherapy
      - Gemcitabine
      - Cisplatin
      - Oxaliplatin
      - Capecitabine
      - 5 fluorouracil (5-FU)
    - Targeted Therapy
      - Pemigatinib
      - Infigratinib (Phase 3)
      - Ivosidenib (Phase 3)
    - Immunotherapy
      - Pembrolizumab (Phase 3)
    - Others
  - , By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Treatment Type
    - Chemotherapy
      - Gemcitabine
      - Cisplatin
      - Oxaliplatin
      - Capecitabine
      - 5 fluorouracil (5-FU)
    - Targeted Therapy
      - Pemigatinib
      - Infigratinib (Phase 3)
      - Ivosidenib (Phase 3)
    - Immunotherapy
      - Pembrolizumab (Phase 3)
    - Others
  - , By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Treatment Type
    - Chemotherapy
      - Gemcitabine
      - Cisplatin
      - Oxaliplatin
      - Capecitabine
      - 5 fluorouracil (5-FU)
    - Targeted Therapy
      - Pemigatinib
      - Infigratinib (Phase 3)
      - Ivosidenib (Phase 3)
    - Immunotherapy
      - Pembrolizumab (Phase 3)
    - Others
  - , By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Treatment Type
    - Chemotherapy
      - Gemcitabine
      - Cisplatin
      - Oxaliplatin
      - Capecitabine
      - 5 fluorouracil (5-FU)
    - Targeted Therapy
      - Pemigatinib
      - Infigratinib (Phase 3)
      - Ivosidenib (Phase 3)
    - Immunotherapy
      - Pembrolizumab (Phase 3)
    - Others
  - , By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Treatment Type
    - Chemotherapy
      - Gemcitabine
      - Cisplatin
      - Oxaliplatin
      - Capecitabine
      - 5 fluorouracil (5-FU)
    - Targeted Therapy
      - Pemigatinib
      - Infigratinib (Phase 3)
      - Ivosidenib (Phase 3)
    - Immunotherapy
      - Pembrolizumab (Phase 3)
    - Others
  - , By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Treatment Type
    - Chemotherapy
      - Gemcitabine
      - Cisplatin
      - Oxaliplatin
      - Capecitabine
      - 5 fluorouracil (5-FU)
    - Targeted Therapy
      - Pemigatinib
      - Infigratinib (Phase 3)
      - Ivosidenib (Phase 3)
    - Immunotherapy
      - Pembrolizumab (Phase 3)
    - Others
  - , By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country/Region
    - South Africa
    - Central Africa
    - North Africa
Company Profiles
- Incyte Corporation*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Eisai Co., Ltd.
- QED Therapeutics, Inc.
- Agios Pharmaceuticals, Inc.
- RenovoRx
- Ability Pharmaceuticals
- Imbrium Therapeutics L.P.
- Delcath Systems, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Global Cholangiocarcinoma Market, Detailed Segmentation:

By Cancer Type:
- Extrahepatic Cholangiocarcinoma
  - Perihilar
  - Distal
- Intrahepatic Cholangiocarcinoma
By Therapy Type:
- Targeted Drug Therapy
  - Pemigatinib
  - Ivosidenib
  - Futibatinib
  - Infigratinib
- Chemotherapy
  - 5-fluorouracil
  - Gemcitabine
  - Cisplatin
  - Capecitabine
  - Oxaliplatin
- Immunotherapy
  - Pembrolizumab
  - Others (Late phase pipeline drugs)
- Others (Pain Medications and others)
By Route of Administration:
- Oral
- Subcutaneous
- Intravenous
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Limited Time Offer - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Download Free Sample Framework of Entire Report (Version 2025)

Interest is driven by :

Business Use – Evaluate our sample report before buying the full report

Personal Use – Explore a sample report to build knowledge

I'm not a robot

reCAPTCHA

Privacy - Terms

I acknowledge that I have read the Privacy Policy

What's Inside the Sample Report?

Current Industry Events of 2025, and Its Impact on the Market
Market Size Estimation – Historical (2020–2024), Current (2025), and Forecast (2025–2032)
Regional Breakdown – North America, Europe, Asia Pacific, Middle East, Africa, and Latin America
Country-Level Analysis – Independent cross segmental analysis across 35 countries.
Competitive Landscape – Company market share analysis, product benchmarking, and detailed Company Profiles for more than 25+ players.
Customer Intelligence – Customers profiles of more than 50 Customers
Segmental Analysis – Market Size, Y-o-Y growth rate, Trends, and use-cases across more than 5 segments, and 25 sub-segments.
Pricing Analysis – Pricing Dashboard, by geographies and by Companies.
Sustainability & Innovation Strategies – Green trends and ESG practices
Key Market Drivers, Challenges & Future Trends – Impact analysis on growth
Customized Insights Section tailored to client-specific questions or industry focus.
Future Outlook – Forecast, future positioning of companies, and futuristic trends.

CHOLANGIOCARCINOMA MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global Cholangiocarcinoma Market, Detailed Segmentation:

By Cancer Type:

By Therapy Type:

By Route of Administration:

By Distribution Channel:

By Geography

EXISTING CLIENTELE

Sales Office (U.S.) :

Menu

Reader Club

Help

Connect With Us :

Secure Payment By :